亚洲 · 股市与财经 · The Edge Singapore
KGI initiates coverage on iX Biopharma with ‘Outperform’ and target price of $1.17
The 12-month target price of $1.17, which is based on sum-of-the-parts valuation, implies a 120.8% upside from the last close of 53 cents.
在 The Edge Singapore 阅读全文 登录后可收藏MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.theedgesingapore.com)
